Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2017 | Pages:
57 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017 Summary Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017, outlays comprehensive information on the Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Catenin Beta 1 (Beta Catenin or CTNNB1) - Catenin beta-1 or ?-catenin is a protein that is encoded by the CTNNB1 gene. In the presence of Wnt ligand, CTNNB1 acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. It is involved in the regulation of cell adhesion, CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. It also acts as a negative regulator of centrosome cohesion. It blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2. The molecules developed by companies in Phase I, Preclinical, Discovery and Unknown stages are 2, 5, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Gastrointestinal, Genetic Disorders and Other Diseases which include indications Colorectal Cancer, Familial Adenomatous Polyposis, Hepatic (Liver) Tumor, Liver Fibrosis, Melanoma, Orphan Diseases, Ovarian Cancer, Pancreatic Cancer, Scar and Solid Tumor. Furthermore, this report also reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Catenin Beta 1 (Beta Catenin or CTNNB1) - The report reviews Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics and enlists all their major and minor projects - The report assesses Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Catenin Beta 1 (Beta Catenin or CTNNB1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Catenin Beta 1 (Beta Catenin or CTNNB1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Catenin Beta 1 (Beta Catenin or CTNNB1) - Overview 7 Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Development 8 Products under Development by Stage of Development 8 Products under Development by Therapy Area 9 Products under Development by Indication 10 Products under Development by Companies 11 Products under Development by Universities/Institutes 13 Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Assessment 15 Assessment by Mechanism of Action 15 Assessment by Route of Administration 17 Assessment by Molecule Type 19 Catenin Beta 1 (Beta Catenin or CTNNB1) - Companies Involved in Therapeutics Development 21 Boston Biomedical Inc 21 Dicerna Pharmaceuticals Inc 21 Marina Biotech Inc 21 Propanac Biopharma Inc 22 Warp Drive Bio Inc 22 Catenin Beta 1 (Beta Catenin or CTNNB1) - Drug Profiles 23 Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Liver Fibrosis - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 BBI-801 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 exisulind - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 M-101 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 M-102 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 M-201 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 nefopam hydrochloride - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Oligonucleotides for Hepatoblastoma - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 PRP - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Small Molecules to Inhibit Beta-Catenin for Oncology - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Synthetic Peptides to Inhibit Beta Catenin for Oncology - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 WX-024 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Catenin Beta 1 (Beta Catenin or CTNNB1) - Dormant Products 43 Catenin Beta 1 (Beta Catenin or CTNNB1) - Product Development Milestones 45 Featured News & Press Releases 45 Sep 27, 2017: Propanc Biopharma Highlights Therapeutic Potential of PRP 45 Aug 30, 2017: Propanc Biopharma Provides Shareholder Update for PRP on Current and Future Activities Leading to Commencement of First-In-Human Studies 45 Aug 02, 2017: Propanc Biopharma Confirms No Treatment Related Findings for PRP in 28-Day Repeat-Dose Toxicity Study 46 Jul 27, 2017: Propanc Biopharma Provides Shareholder Update on R&D Activities for PRP 47 Jul 20, 2017: Propanc Biopharma Receives Acceptance of Key Patent Application for Cancer Treatment in China 48 Jun 27, 2017: ScarX Achieves Full Enrollment in Human Scar Reduction Trial Safety and Efficacy Results Targeted for Late 2017 48 Jun 26, 2017: Propanc Biopharma Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer 49 Jun 09, 2017: Propanc Biopharma Makes Significant Progress with PCT Patent Application 50 May 19, 2017: Propanc Biopharma Highlights PRP's Potential to Reprogram Cancer Stem Cells 50 May 16, 2017: Propanc Biopharma Awaits FDA Response to Orphan Drug Designation Request for Treatment of Pancreatic Cancer, as PRP Progresses to First-In-Human Studies 51 May 02, 2017: Propanc Biopharma Provides Update on Investigational Medicinal Product Manufacture of PRP for First-In-Human Studies 52 Apr 27, 2017: Propanc Successfully Completes 28-Day Repeat-Dose Toxicity Study for PRP 53 Apr 04, 2017: Boston Biomedical Presents New Preclinical Data on BBI-801 at AACR 2017 Highlighting the Potential Role of Cancer Stemness Inhibition 53 Feb 14, 2017: Propanc Successfully Completes Low Dose Group for GLP-Compliant 28-Day Repeat-Dose Toxicity Study 54 Jan 24, 2017: Propanc Provides Progress Update on Additional Patent Applications 55 Appendix 56 Methodology 56 Coverage 56 Secondary Research 56 Primary Research 56 Expert Panel Validation 56 Contact Us 56 Disclaimer 57
List of Tables
Number of Products under Development by Stage of Development, H2 2017 8 Number of Products under Development by Therapy Areas, H2 2017 9 Number of Products under Development by Indication, H2 2017 10 Number of Products under Development by Companies, H2 2017 11 Products under Development by Companies, H2 2017 12 Number of Products under Investigation by Universities/Institutes, H2 2017 13 Products under Investigation by Universities/Institutes, H2 2017 14 Number of Products by Stage and Mechanism of Actions, H2 2017 16 Number of Products by Stage and Route of Administration, H2 2017 18 Number of Products by Stage and Molecule Type, H2 2017 20 Pipeline by Boston Biomedical Inc, H2 2017 21 Pipeline by Dicerna Pharmaceuticals Inc, H2 2017 21 Pipeline by Marina Biotech Inc, H2 2017 22 Pipeline by Propanac Biopharma Inc, H2 2017 22 Pipeline by Warp Drive Bio Inc, H2 2017 22 Dormant Products, H2 2017 43 Dormant Products, H2 2017 (Contd..1), H2 2017 44
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
